U.S. FDA approves Symdeko (ivacaftor/tezacaftor and ivacaftor) Tablets for the treatment of Cystic Fibrosis

Vertex Pharmaceuticals receives FDA approval for Symdeko (ivacaftor/tezacaftor and ivacaftor) tablets for the treatment of Cystic Fibrosis

Company: Vertex Pharmaceuticals Incorporated

Brand Name: Symdeko

Generic Name: ivacaftor/tezacaftor and ivacaftor

Dosage: Tablets

Treatment For: Cystic Fibrosis

General information about Symdeko

Symdeko (ivacaftor/tezacaftor tablets and ivacaftor tablets) is a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator and CFTR corrector combination for the treatment of cystic fibrosis (CF) in patients aged 12 years and older who have two copies of the F508del mutation, or who have at least one mutation in the CF gene that is responsive to treatment with Symdeko.